1 / 13

Paris- RP

Lille. Rouen. Caen. Reims. Paris- RP. Nancy. Strasbourg. Angers. Rennes. Tours. Nantes. Dijon. Besançon. Poitiers. Lyon. Bordeaux. Toulouse. Nice. Montpellier. Marseille. GSF: Groupe Sarcome Français GETO: Groupe d’Etudes des Tumeurs Osseuses. N = 36 institutions

chumani
Télécharger la présentation

Paris- RP

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lille Rouen Caen Reims Paris- RP Nancy Strasbourg Angers Rennes Tours Nantes Dijon Besançon Poitiers Lyon Bordeaux Toulouse Nice Montpellier Marseille GSF: Groupe Sarcome Français GETO: Groupe d’Etudes des Tumeurs Osseuses N = 36 institutions Sarcoma Database: 3300 pts Frozen tissue bank: 1300 sarcomas Villejuif Clermont-Ferrand

  2. Sarcome 01 Euro-Ewing 99 PI :Dr O. Oberlin – Villejuif Molecular analysis on Iry: 448 patients (79 %) BM: 326 patients (57%) 30 sept 06 Suspension of R1 randomization

  3. Sarcome 02 PALSAR II PI :Dr N B BUI – Bordeaux Main end-point: overall survival Statistical hypothesis: 3-yr OS: 40% vs 15% (N® per arm: 50) October 06: N = 207 patients N® = 65/100 patients

  4. Sarcome 03 Osteosarcoma PI :A Le Cesne – Villejuif Localized operable osteosarcoma API-AI regimen 4 CT courses Main end-point: histological response rate Good histological response: 37% ASCO 06 2-yr overall survival: 86% 2-yr PFS 74% Follow-up

  5. Sarcome 04 EWING PI :O Oberlin – Villejuif D1 D8 D15 D21 D28/1 D8 D15 D21 D28 CDDP VP-16 Main end-point: Objective response rate Statistical hypothesis: Simon: at least 6/29 OR October 2006 = 44/45 ASCO 07

  6. Sarcome 05 Desminib PI :JY Blay – Lyon Progressive AF/Desmoid T Glivec®: 400 mg/d 800 mg/d if PD Duration: one year Main end-point: 3-month PFS (at least 7 patients not PD) At 3 month: 1 CR, 1 PR, 31 SD, 5 PD ASCO 06 6-m PFS 73%; 1-yr PFS 69% Translational research ongoing imatinib Random NSAID

  7. Sarcome 06: Angiotax PI :N Penel – Lille Angiosarcoma 2nd/3rd CT line Weekly taxol: 80 mg/w 3 weeks on, 1 off Main end-point: Objective response rate Statistical hypothesis: Simon two step: 15 + 10 patients at least 6/25 OR Secondary end-point: PFS, OS, tolerance Translational research ASCO 2007

  8. Sarcome 07 Taxogem PI :F. Duffaud – Marseille P. Pautier - Villejuif ® phase II Leiomyosarcoma Uterine vs other 2nd CT line N = 40 + 40 Main end-point: OR Secondary end-point: PFS, OS, tolerance, QOL N = 13/80

  9. Sarcome 08:Adjuvant GIST EORTC 62024 PI (FSG) :A Le Cesne – Villejuif Participating French centers : 42 Mutational analysis: 70% October 2006 N = 418

  10. Sarcome 09 OS 2006 PI :F Duffaud – Curie / L Brugieres - Villejuif Intergroup SFCE/GSF/GETO Adult/children OS – phase III Zoledronate N = 470 3-yr EFS > 13% in exp arm Translational research

  11. Sarc-Gyn 1 Adjuvant CT PI:P Pautier – Villejuif Uterine leiomyoS, carcinoS, high grade endometrial S N = 52 / 256 3-yr EFS > 20% in experimental arm Arm A 4 x API RTE 45 Gy + Brachytherapy 15 Gy A (50), I ( 6), C (75) Surgery < 6 wR • RTE 45 Gy + Brachytherapy 15 Gy • Arm B

  12. BFR 14 trial - Advanced GIST(June 2002) PI :J.Y Blay – Lyon A. Le Cesne - Villejuif Stop Imatinib Non PD R Imatinib N patients included in October 2005:271 1) N randomized (interrupted) pts at 1 year: 58 (ASCO 04,05) Stop imatinib arm: 32 imatinib arm: 26 2) N randomized (ongoing) pts at 3 years: 32 (ASCO 07)

  13. AB1010 first line - Advanced GIST PI :A. Le Cesne - Villejuif Day 1 Preclinical efficacy profile > to IM IC50 < 0.005 µM vs IC50 = 0.02 µM Phase II AB1010: 7.5 mg/kg 4 centers N = 25 (06/05 to 11/06) ASCO 2007 Day 1 M6 M1

More Related